[{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"PF614","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Copernicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"DNA Nanoparticle-based Gene Therapy","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Achieve Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"TNX-1300","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Phoenix Pharmalabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"PPL-138","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Stalicla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Cessation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Gilgamesh Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Camino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"EpiVario","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"14","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"}]

Find Clinical Drug Pipeline Developments & Deals by National Institute on Drug Abuse

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The grant will be used to advance the company's research towards developing a novel epigenetic regulator as a treatment for opioid use disorder (OUD).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 01, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : EpiVario

                          Deal Size : $0.2 million

                          Deal Type : Funding

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for Opioid-Related Disorders.

                          Brand Name : GM-3009

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Ibogaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Gilgamesh Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : BioCorRx will focus funding on clinical development of BICX104 (naltrexone) in combination with Bupropion, currently in preclinical studies for methamphetamine use disorder.

                          Brand Name : BICX104

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 28, 2024

                          Lead Product(s) : Naltrexone,Bupropion Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : BioCorRx

                          Deal Size : $11.0 million

                          Deal Type : Funding

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will fund longer toxicology studies and manufacturing of SBP-9330, a small molecule targeting mGlu2 receptor, to support planned Phase 2 trials for nicotine cessation.

                          Brand Name : SBP-9330

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 06, 2024

                          Lead Product(s) : SBP-9330

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Recipient : Camino Pharma

                          Deal Size : $9.0 million

                          Deal Type : Funding

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding will support development of a subcutaneous formulation of its anti-fentanyl monoclonal antibody, CSX-1004 SQ, an investigational product that has successfully entered Phase 1 studies for the reversal of acute opioid over dose of fentanyl and ...

                          Brand Name : CSX-1004

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 18, 2023

                          Lead Product(s) : CSX-1004

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Recipient : Cessation Therapeutics

                          Deal Size : $14.8 million

                          Deal Type : Funding

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...

                          Brand Name : TRN-228

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 28, 2023

                          Lead Product(s) : Cebranopadol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Recipient : Tris Pharma Inc

                          Deal Size : $16.6 million

                          Deal Type : Funding

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding will be used for the development of SiteOne's selective NaV1.8 inhibitor, STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.

                          Brand Name : STC-004

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 18, 2023

                          Lead Product(s) : STC-004

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : SiteOne Therapeutics

                          Deal Size : $15.0 million

                          Deal Type : Funding

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).

                          Brand Name : OMS527

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 10, 2023

                          Lead Product(s) : OMS527

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Recipient : Omeros

                          Deal Size : $6.6 million

                          Deal Type : Funding

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

                          Brand Name : STP7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 08, 2023

                          Lead Product(s) : Mavoglurant

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Stalicla

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Funding from the grant will support the study of company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD) and the cost of advancing PPL-138 through its remaining preclinical studies and through Phase 1 human clinical trials.

                          Brand Name : PPL-138

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 06, 2022

                          Lead Product(s) : PPL-138

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Phoenix Pharmalabs

                          Deal Size : $8.7 million

                          Deal Type : Funding

                          blank